Paragon 28 Welcomes New Board Member Dave Demski
Paragon 28, Inc. (NYSE: FNA), a prominent leader in the field of foot and ankle surgical solutions, is excited to announce the recent appointment of Dave Demski as an independent director. This strategic move expands the Board of Directors from eight to nine members, enhancing the company’s governance and oversight capabilities during a crucial phase of growth.
Dave Demski's Expertise and Leadership
Dave Demski brings an extensive background of experience to Paragon 28, having spent over two decades in executive leadership roles within the orthopedic sector. His most recent position was as the President and CEO of Globus Medical, where he led the company through significant growth and innovative milestones from August 2017 to April 2022. Prior to his role as CEO, he held key positions including CFO and COO, which highlights his multifaceted skills in organizational leadership.
In addition to his experience at Globus Medical, Mr. Demski has a significant track record on public company boards. He played a vital role on Globus Medical’s board from its inception and is currently serving on the board of directors of Alphatec Spine (NASDAQ: ATEC) since October 2023. Previously, he also contributed to Axonics, Inc. until its recent acquisition by Boston Scientific.
Impact on Paragon 28's Mission
Albert DaCosta, the Chairman and CEO of Paragon 28, expressed enthusiasm about Mr. Demski's appointment: “We are thrilled to welcome Dave to our Board of Directors during this pivotal time. His extensive industry knowledge, leadership experience, and operational expertise will be invaluable to Paragon 28 as we continue to advance our mission of improving foot and ankle patient outcomes.”
Reflecting on his new role, Dave Demski stated, “I am honored to join the Board of Directors at Paragon 28 and to contribute to the company’s incredible mission of transforming the foot and ankle market. I look forward to collaborating with the Board and the company's leadership to continue driving innovation and positively impacting the lives of patients suffering from foot and ankle conditions globally.”
About Paragon 28, Inc.
Paragon 28, headquartered in Englewood, CO, is a pioneering medical device company solely focused on the orthopedic foot and ankle market. With a commitment to improving patient lives, the company has been at the forefront of innovative solutions, procedural approaches, and instrumentation that cater to a wide array of foot and ankle conditions. These conditions range from fracture fixation and forefoot to progressive collapsing foot deformity (PCFD) and Charcot foot, supporting both patients and surgeons in achieving optimal outcomes.
Paragon 28 designs its products with a clear focus on effectiveness, aiming to reduce ailment recurrence and complication rates while streamlining surgical procedures to be simpler, consistent, and reproducible.
Frequently Asked Questions
Who is Dave Demski?
Dave Demski is the newly appointed independent director of Paragon 28, with extensive experience in the orthopedic industry, especially as the former CEO of Globus Medical.
What will Dave Demski bring to Paragon 28?
His leadership and operational expertise, gained from over two decades in the industry, will enhance the company's strategic direction and strengthen its governance.
What is the mission of Paragon 28?
The mission of Paragon 28 is to advance foot and ankle patient outcomes by providing innovative orthopedic solutions and improving surgical procedures.
How has the Board of Directors changed at Paragon 28?
The Board expanded from eight to nine members with the addition of Dave Demski, enhancing the company's governance capabilities.
What types of products does Paragon 28 offer?
Paragon 28 offers a variety of orthopedic solutions, addressing conditions such as fracture fixation, flatfoot, and Charcot foot, among others.
